OncoVista Innovative Therapies, Inc. is a biopharmaceutical firm focused on creating highly specific treatments for cancer. Their methodology involves harnessing tumor-associated biomarkers to target these therapies. The company's investigational drug candidates include Cordycepin (OVI-123), which is currently progressing through Phase I/II clinical trials as a potential therapy for stubborn TdT-positive leukemias. Additionally, L-Nucleoside Conjugates (OVI-117) are in the pre-clinical research phase, being explored for their efficacy against colon cancer. This enterprise was established in 2004 and is based in San Antonio, Texas.